UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom Read more
Prof. Paul MIDGLEY
Professor Paul Midgley FRS is Head of Department and Professor of Materials Science in the Department of Materials Science and Metallurgy in the University of Cambridge. Until his appointment as HoD he was Director of the Wolfson Electron Microscope Suite. His research interests lie primarily in transmission electron microscopy and in recent years has focused on the development of electron tomography, electron crystallography and precession electron diffraction, and energy loss spectroscopy and their application to nanoscale organic and inorganic materials. He sits on the Editorial Boards of a number of journals and was for many years Editor-in-Chief of the journal Ultramicroscopy.
Dr Christopher PHILLIPS
ASTRAZENECA, Cambridge, United Kingdom
Dr Chun-wa CHUNG
GLAXOSMITHKLINE, Stevenage, United Kingdom Read more
Dr Chun-wa CHUNG
Chun-wa currently leads the UK structural and biophysical science group at GSK’s major European research site in Stevenage. This group supports crystallography, electron microscopy, structural mass spectrometry and biophysical studies from HTS hit triage and mode-of-action analysis to fragment screening across a wide range of therapeutic areas and drug modalities (e.g. small molecule, biopharmaceuticals, CGT). She joined GSK after a degree in Natural Sciences (Chemistry) and PhD in NMR method development both at the University of Cambridge. Since then she has led and supported many project teams with a wide repertoire of structural and biophysical techniques. As well as leading the introduction of new technologies into GSK, such as medium throughput surface plasmon resonance for hit triage, Rapidfire MS for compound screening and most recently, HDX-MS and EM for molecular binding and mechanistic elucidation.
Dr Rebecca Ebenhoch is a Research scientist at Boehringer Ingelheim Pharma GmbH & Co. KG in Biberach. Having previously done a post-doc at SGC in Oxford, her research interest lies on structure guided drug design using X-ray crystallography and Cryo-EM as well as on biophysical protein characterization.
Dr Alexey Rak has a M.sc in Biology Genetics, and in Biochemistry. He then competed PhDs in Biochemistry and Biophysics working on protein biosynthesis machinery characterization. He did his Post-doc and then held a Group Leader Position at Max-Planck Institute for Molecular Physiology in Germany working in the field of vesicular membrane trafficking. For his work he was awarded several honours including European Young Investigator Award in 2004. Since 2007 Alexey joined Sanofi in Paris where he has developed new methods to characterize biophysical properties of proteins including biologics and enabling the lead discovery of challenging protein targets. Since 2014 he is heading Bio Structure and Biophysics Department at integrated Drug Discovery in Sanofi.
Dr Jeremy REES
THERMO FISHER SCIENTIFIC, Mow Cop, United Kingdom Read more
Dr Jeremy REES
Dr Jeremy Rees received his PhD in electron microscopy of parasites from the University of East Anglia. He went on to work for Sanofi where he setup and ran an the international center for Electron Microscopy. Since 1996 he has worked for what is now Thermo Fisher in various roles from application science to sales and marketing. He is currently Strategic Account Manager enabling the adoption of Cryo-EM at pharma companies throughout Europe.
Jason has recently joined the Industrial Liaison Office (May 2017) as a cryo-electron microscopy scientist where he will be supporting industry clients seeking advanced imaging capabilities of eBIC. Recent developments in detectors and the latest generation of microscopes have brought about a “resolution revolution” and consequent renaissance in the field of EM. Previously unattainable resolutions are now routinely possible and researchers from both academia and industry are clamoring to access the technology.
He has experience in both X-ray crystallography and EM having utilised both techniques first in his PhD studies at the University of Cape Town to solve the structure of a large novel metabolic enzyme from Bacteroides fragilis. He followed this up with a post-doctorate at the EMBL in Grenoble where he again applied these methods to studying native complexes and proteins with potential as drug targets against the pathogen Toxoplasma gondii.
Jason aims to leverage the state-of-the-art capabilities here at eBIC to provide novel and previously unattainable structural insights for the drug-discovery and biotech industries.
Denis Zeyer is CEO of NovAliX a client-centric organization providing expert driven innovative outsourcing and insourcing research services for drug discovery. Core expertize includes synthetic organic chemistry expertise, FBDD and SBDD. The comprehensive portfolio of biophysical and analytical technologies include: chemical microarray SPR, native MS, NMR, Biacore, ITC as well as strong structural biology expertise based on x-ray crystallography and electron microscopy.